Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpop...

by APHINITY Steering Committee and Investigators, Bines, J., Caballero, C., Cameron, D., Cardoso, F., Clark, E., Cole, B.F, de Azambuja, E., Frank, E., Fumagalli, D., Gelber, R.D, Heeson, S., Kiermaier, A., Krop, I., Loi, S., Loibl, S., Piccart-Gebhart, M., Procter, M., Restuccia, E., Salgado, R., Tjan-Heijnen, V., Wang, X.V
Published 2022

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

by Ballestrero, A., Benelli, M., Bergqvist, M., Bernardo, A., Bliss, J.M, Bonetti, A., Breast International Group and PYTHIA Collaborators, Cameron, D., Colleoni, M., Davies, D.M, De Swert, H., Duhoux, F.P, Fumagalli, D., Gebhart, G., Henry, S., Hilbers, F.S, Ignatiadis, M., International Breast Cancer Study Group, Jerusalem, G., Kammler, R., Loi, S., MacPherson, I.R, Maibach, R., Malorni, L., McCartney, A., Migliaccio, I., Neven, P., Papadimitriou, K., Piccart, M., Regan, M.M, Ruepp, B., Seles, E., Thomson, A., Tyekucheva, S., Zoppoli, G.
Published 2022